Reviva Pharmaceuticals Holdings Inc (RVPH) - News Archive

Brilaroxazine, a promising therapeutic candidate for schizophrenia, has once again displayed encouraging outcomes in the latest long-term open-label extension of the Phase 3 RECOVER study. Reviva Pharmaceuticals Holding...

Vocal Biomarker Data Highlights Efficacy of Brilaroxazine in Schizophrenia Treatment: Insights from the Phase 3 RECOVER Trial Reviva Pharmaceuticals Holdings Inc. has made significant strides in the pharmacological trea...

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of Underwritten Offering and Previous Registered Direct OfferingCUPERTINO, Calif., Aug. 21, 2024 - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-sta...

CSIMarket.com is pleased to present a groundbreaking article that highlights the recent European patent grant covering the use of brilaroxazine for the treatment of pulmonary hypertension (PH). This patent encompasses t...

Reviva Pharmaceuticals Holdings, Inc. recently concluded its registered direct offering, raising $3 million through the sale and issuance of common stock shares and accompanying warrants priced at-the-market under Nasda...

Reviva Pharmaceuticals Holdings, Inc. Announces $3 Million Registered Direct Offering Priced At-the-MarketReviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) recently revealed plans for a registered direct offering pri...

Reviva s Brilaroxazine Continues to Show Promise in Schizophrenia Treatment StudyReviva Pharmaceuticals, Inc. has recently provided an enrollment update for its open-label extension study evaluating Brilaroxazine in sch...

In a recent development, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) finds itself under scrutiny as Pomerantz LLP, a renowned law firm, launches an investigation into claims made by investors. The potential imp...

CSIMarket.com NEW YORK, May 11, 2024 - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a biopharmaceutical company focused on developing innovative therapeutics, is currently under scrutiny as Rosen Law Firm, a le...

Reviva Announces Exciting Progress in Brilaroxazine Clinical Trials for NDA in Schizophrenia- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study -In a major milestone for Reviva Pharmaceuticals, the...

Schizophrenia is a chronic and debilitating psychiatric disorder that affects millions of individuals worldwide. Despite significant advancements in the understanding of its pathophysiology, there is still a need for mo...

is pleased to present an exclusive analysis of the topline data from the Phase 3 RECOVER Trial of Brilaroxazine in schizophrenia. This groundbreaking study, conducted by pharmaceutical company Reviva, promises significa...